A Phase I/II Study to Evaluate the Safety, Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Entinostat (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2019 Planned End Date changed from 31 Jan 2020 to 31 Jan 2021.
- 29 Jan 2019 Planned primary completion date changed from 31 Jan 2019 to 31 Jan 2020.
- 05 Jan 2018 Status changed from active, no longer recruiting to recruiting.